Literature DB >> 17533375

Mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic syndrome impair AML1- and p53-mediated transcription.

X-L Li1, Y Arai, H Harada, Y Shima, H Yoshida, S Rokudai, Y Aikawa, A Kimura, I Kitabayashi.   

Abstract

The AML1 transcription factor complex is the most frequent target of leukemia-associated chromosomal translocations. Homeodomain-interacting protein kinase 2 (HIPK2) is a part of the AML1 complex and activates AML1-mediated transcription. However, chromosomal translocations and mutations of HIPK2 have not been reported. In the current study, we screened mutations of the HIPK2 gene in 50 cases of acute myeloid leukemia (AML) and in 80 cases of myelodysplastic syndrome (MDS). Results indicated there were two missense mutations (R868W and N958I) in the speckle-retention signal (SRS) domain of HIPK2. Subcellular localization analyses indicated that the two mutants were largely localized to nuclear regions with conical or ring shapes, and were somewhat diffused in the nucleus, in contrast to the wild type, which were mainly localized in nuclear speckles. The mutations impaired the overlapping localization of AML1 and HIPK2. The mutants showed decreased activities and a dominant-negative function over wild-type protein in AML1- and p53-dependent transcription. These findings suggest that dysfunction of HIPK2 may play a role in the pathogenesis of leukemia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17533375     DOI: 10.1038/sj.onc.1210523

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  34 in total

1.  PML activates transcription by protecting HIPK2 and p300 from SCFFbx3-mediated degradation.

Authors:  Yutaka Shima; Takito Shima; Tomoki Chiba; Tatsuro Irimura; Pier Paolo Pandolfi; Issay Kitabayashi
Journal:  Mol Cell Biol       Date:  2008-09-22       Impact factor: 4.272

2.  HIPK2 is necessary for type I interferon-mediated antiviral immunity.

Authors:  Lili Cao; Guang Yang; Shandian Gao; Chunxia Jing; Ruth R Montgomery; Yuxin Yin; Penghua Wang; Erol Fikrig; Fuping You
Journal:  Sci Signal       Date:  2019-03-19       Impact factor: 8.192

Review 3.  Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia.

Authors:  Yan Liu; Zhiheng Cheng; Yifan Pang; Longzhen Cui; Tingting Qian; Liang Quan; Hongyou Zhao; Jinlong Shi; Xiaoyan Ke; Lin Fu
Journal:  J Hematol Oncol       Date:  2019-05-24       Impact factor: 17.388

4.  Circular RNAs in leukemia.

Authors:  Tuğçe Balci Okcanoğlu; Cumhur Gündüz
Journal:  Biomed Rep       Date:  2018-12-10

Review 5.  Posttranslational modifications regulate HIPK2, a driver of proliferative diseases.

Authors:  Vera V Saul; M Lienhard Schmitz
Journal:  J Mol Med (Berl)       Date:  2013-04-25       Impact factor: 4.599

Review 6.  Oncogene-induced senescence: an essential role for Runx.

Authors:  Anna Kilbey; Anne Terry; Ewan R Cameron; James C Neil
Journal:  Cell Cycle       Date:  2008-05-29       Impact factor: 4.534

7.  PEBP2-beta/CBF-beta-dependent phosphorylation of RUNX1 and p300 by HIPK2: implications for leukemogenesis.

Authors:  Hee-Jun Wee; Dominic Chih-Cheng Voon; Suk-Chul Bae; Yoshiaki Ito
Journal:  Blood       Date:  2008-08-11       Impact factor: 22.113

8.  Src kinase modulates the apoptotic p53 pathway by altering HIPK2 localization.

Authors:  Tilman Polonio-Vallon; Joanna Kirkpatrick; Jeroen Krijgsveld; Thomas G Hofmann
Journal:  Cell Cycle       Date:  2013-10-25       Impact factor: 4.534

9.  Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF-1alpha.

Authors:  Lavinia Nardinocchi; Rosa Puca; Ada Sacchi; Gideon Rechavi; David Givol; Gabriella D'Orazi
Journal:  PLoS One       Date:  2009-08-28       Impact factor: 3.240

10.  HIPK2 modulates p53 activity towards pro-apoptotic transcription.

Authors:  Rosa Puca; Lavinia Nardinocchi; Ada Sacchi; Gideon Rechavi; David Givol; Gabriella D'Orazi
Journal:  Mol Cancer       Date:  2009-10-14       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.